Q1 2026 Vimian Group AB Earnings Call Transcript
Key Points
- Vimian Group AB (FRA:0V0) reported double-digit growth in three out of four segments: Specialty Pharma, Veterinary Services, and Diagnostics, outperforming the global animal health market.
- The company completed two acquisitions in Q1, adding approximately EUR10 million in annual revenues, and signed an agreement for a third acquisition, marking its entry into the Irish market.
- Operational cash conversion remained strong at over 70%, indicating efficient cash management.
- Specialty Pharma segment achieved 10% organic growth, driven by strong performance in Allergy and Specialized Nutrition, and launched 17 new products.
- The MedTech Dental operation delivered double-digit revenue growth with expanding margins, showcasing successful integration and growth post-acquisition of iM3.
- Adjusted EBITA grew only 3% to EUR29.2 million, with a margin decrease due to investments in MedTech Orthopedics and new market entries.
- US Orthopedics experienced a slight decline in growth, reflecting challenges in the current market situation.
- The Diagnostics segment's profitability was impacted by product mix, with higher US extraction sales affecting margins.
- Net debt increased to EUR258.4 million, up from EUR245.4 million at the end of the previous quarter.
- The company faced a write-down of shares in associates amounting to minus EUR2.5 million, impacting overall financial performance.
Welcome to Vimian Group AB Q1 Report 2026 presentation. (Operator Instructions)
Now, I will hand the conference over to the speakers, CEO, Alireza Tajbakhsh and CFO, CarlâJohan Zetterberg Boudrie. Please go ahead.
Good morning, everyone, and welcome to Vimianâs firstâquarter earnings call 2026. Iâm Alireza Tajbakhsh, Group CEO, and I will present the firstâquarter results together with our CFO, CarlâJohan Zetterberg Boudrie. Q1 is always an active period for us at Vimian, with a strong cadence of industry and client events. This provides an early read on customer sentiment, we get valuable feedback across our big businesses, opportunities to engage with industry peers, and so on.
Itâs encouraging to see that the strong traffic boost, high engagement, and the positive feedback we get from veterinarians from these events are also reflected in a strong start to the year, with positive momentum across the Group. Three out of four of our segments: Specialty Pharma, Veterinary Services,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
